REGENXBIO Inc.

REGENXBIO Inc. is a clinical-stage biotechnology company focused on developing gene therapies for patients with genetic defects. The company's therapies are based on its proprietary NAV Technology Platform, which uses adeno-associated virus vectors to deliver functional genes to target cells. Key pipeline candidates include ABBV-RGX-314 for wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; RGX-202 for Duchenne muscular dystrophy; RGX-121 for mucopolysaccharidosis type II; and RGX-111 for mucopolysaccharidosis type I. The company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical firms.

REGENXBIO Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol RGNX. Its shares are traded in U.S. dollars (USD), reflecting its primary listing in the United States. As a U.S.-based company, its financial reporting and stock trading are conducted in USD.

REGENXBIO Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing gene therapies for serious genetic and retinal diseases. The company's work involves advanced gene delivery technologies and collaborations with larger pharmaceutical partners to bring potential treatments through clinical trials and toward regulatory approval.

REGENXBIO Inc. is headquartered in Rockville, Maryland, United States. The company primarily serves the U.S. market, but it also has international collaborations. For instance, it has a collaboration and license agreement with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. Additionally, its partnership with AbbVie Global Enterprises Ltd. for ABBV-RGX-314 targets global markets for retinal diseases.

REGENXBIO generates revenue primarily through licensing its proprietary NAV Technology Platform to other biotechnology and pharmaceutical companies, as well as through collaboration agreements. Key partnerships include a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 for retinal diseases, and an agreement with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 for lysosomal storage disorders outside the United States. The company also advances its own pipeline candidates, which may lead to future product revenues upon approval.